The majority of congenital disorders of glycosylation (CDG) are caused by defects of dolichol (Dol)-linked oligosaccharide assembly, which lead to under-occupancy of Nglycosylation sites. Most mutations encountered in CDG are hypomorphic, thus leaving residual activity to the affected biosynthetic enzymes. We hypothesized that increased cellular levels of Dol-linked substrates might compensate for the low biosynthetic activity and thereby improve the output of protein N-glycosylation in CDG. To this end, we investigated the potential of the squalene synthase inhibitor zaragozic acid A to redirect the flow of the polyisoprene pathway toward Dol by lowering cholesterol biosynthesis. The addition of zaragozic acid A to CDG fibroblasts with a Dol-PMan synthase defect led to the formation of longer Dol-P species and to increased Dol-P-Man levels. This treatment was shown to decrease the pathologic accumulation of incomplete Dol pyrophosphate-GlcNAc 2 Man 5 in Dol-P-Man synthasedeficient fibroblasts. Zaragozic acid A treatment also decreased the amount of truncated protein N-linked oligosaccharides in these CDG fibroblasts. The increased cellular levels of Dol-P-Man and possibly the decreased cholesterol levels in zaragozic acid A-treated cells also led to increased availability of the glycosylphosphatidylinositol anchor as shown by the elevated cell-surface expression of the CD59 protein. This study shows that manipulation of the cellular Dol pool, as achieved by zaragozic acid A addition, may represent a valuable approach to improve N-linked glycosylation in CDG cells.
Congenital disorders of glycosylation (CDG)3 are a group of inherited defects of protein glycosylation (1). Mutations in genes encoding either proteins involved in biosynthesis of lipid-linked oligosaccharide (LLO) required for N-glycosylation (2) or proteins involved in glycan processing (3, 4) or transport of N-glycoproteins (5) form the molecular basis of CDG. The majority of CDG encompass disorders affecting the assembly of the LLO precursor dolichol pyrophosphate (Dol-PP)-GlcNAc 2 Man 9 Glc 3 , which lead to under-occupancy of N-glycosylation sites (6). The stepwise biosynthesis of the LLO precursor begins at the cytosolic side of the endoplasmic reticulum membrane by transfer of GlcNAc-P to Dol-P and completes at the luminal side of the endoplasmic reticulum membrane. Dol-P serves not only as a carrier of maturing LLO but also as a lipid component of Dol-P-Man and Dol-PGlc, both donor substrates for luminally acting mannosyl-and glucosyltransferases (7).The symptoms associated with CDG are principally of neurologic nature, such as psychomotor retardation, ataxia, and hypotonia, but also include hormonal alterations and coagulopathies (8). The clinical severity of CDG depends mainly on the degree of N-glycosylation site under-occupancy (9), which itself depends on the available pool of the complete LLO Dol-PP-GlcNAc 2 Man 9 Glc 3 . To date, only two forms of CDG can be successfully treated by oral carbohydrate supplementation. The glycosylation d...